Indian Journal of Cancer Home 

ORIGINAL ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2018  |  Volume : 55  |  Issue : 3  |  Page : 288--291

Metastatic thymic epithelial tumors: A regional cancer center experience

KC Lakshmaiah, Tamojit Chaudhuri, Govind K Babu, Lokanatha Dasappa, Linu Abraham Jacob, M C Suresh Babu, AH Rudresha, KN Lokesh, LK Rajeev 
 Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India

Correspondence Address:
Dr. Tamojit Chaudhuri
Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka
India

BACKGROUND: Thymic epithelial tumors (TET) are the most common tumors of the anterior mediastinum. Patients with advanced/metastatic disease are usually treated with palliative chemotherapy (CT). Unfortunately, even though various palliative CT regimens have been used for long time, there is a real scarcity of published Indian data regarding the experience of palliative CT in metastatic TET (mTET). MATERIALS AND METHODS: This is a retrospective analysis of mTET patients treated between January 2010 and September 2017. Patients who received at least three cycles of first-line palliative CT were included for analysis of response rates, toxicity, and survival and prognostic factors. RESULTS: Of the 49 mTET patients, 27 (55.1%) were males. The median age at diagnosis was 52 years (range: 25–65). Eighteen patients (36.7%) had Masaoka Stage IVa disease, and the rest of the patients had IVb disease. The most common site of metastasis was pleuropericardium (n = 18), followed by lungs (n = 16) and lymph nodes (n = 9). The median progression-free survival and overall survival (OS) were 11.2 months (95% confidence interval [CI], 8.7–13.6) and 20.2 months (95% CI, 17.1–22.8), respectively, for the whole cohort (n = 49). The median OS of patients with Stage IVa disease was significantly better than that of the patients with Stage IVb disease (log-rank P = 0.000). Moreover, the “responders” to first-line CT had a significantly better median OS than the “nonresponders” (log-rank P = 0.000). Various first-line palliative CT regimens were well tolerated in our patients. CONCLUSION: Adriamycin Cisplatin Vincristine Cyclophosphamide (ADOC), Cyclophosphamide Adriamycin Cisplatin, and paclitaxel + carboplatin all are viable first-line palliative CT options for mTET and showed a comparable survival in Indian patients. The present study suggested that “responders” to first-line CT and those with Stage IVa disease might have a better survival than “nonresponders” and those with Stage IVb disease, respectively.


How to cite this article:
Lakshmaiah K C, Chaudhuri T, Babu GK, Dasappa L, Jacob LA, Babu M C, Rudresha A H, Lokesh K N, Rajeev L K. Metastatic thymic epithelial tumors: A regional cancer center experience.Indian J Cancer 2018;55:288-291


How to cite this URL:
Lakshmaiah K C, Chaudhuri T, Babu GK, Dasappa L, Jacob LA, Babu M C, Rudresha A H, Lokesh K N, Rajeev L K. Metastatic thymic epithelial tumors: A regional cancer center experience. Indian J Cancer [serial online] 2018 [cited 2020 Nov 25 ];55:288-291
Available from: https://www.indianjcancer.com/article.asp?issn=0019-509X;year=2018;volume=55;issue=3;spage=288;epage=291;aulast=Lakshmaiah;type=0